Search

Your search keyword '"Ryotaro Morinaga"' showing total 6 results
Start Over Author "Ryotaro Morinaga" Journal journal of thoracic oncology
6 results on '"Ryotaro Morinaga"'

1. P21.01 Phase I Study of Carboplatin/Nab-Paclitaxel and Concurrent TRT in Elderly Patients with Unresectable Locally Advanced NSCLC

Author

Hiroshige Yoshioka, Ryotaro Morinaga, Takayasu Kurata, Takashi Takahashi, Haruko Daga, Shota Omori, Y. Tsuboguchi, Hideyuki Harada, Y. Hisamatsu, and Keita Mori

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Locally advanced, Carboplatin, Phase i study, chemistry.chemical_compound, chemistry, Internal medicine, medicine, business, Nab-paclitaxel
Published
2021

2. Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

Author

Shinsuke Tsumura, Akihito Okazaki, Yasushi Goto, Ryotaro Morinaga, Manabu Ono, Shoji Tokunaga, Akinobu Hamada, Masahiro Seike, Akihiro Bessho, Hiroaki Akamatsu, Yoichi Nakanishi, Haruyasu Murakami, Hiroyuki Sakashita, Yuka Fujita, Taishi Harada, Eiji Iwama, Yoshiaki Mori, Noriaki Nakagaki, Kenji Sugio, Isamu Okamoto, Takayuki Shimose, Nobuyuki Yamamoto, and Shinichiro Ushijima

Subjects
Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Alectinib, medicine.medical_specialty, Lung Neoplasms, Carbazoles, Phases of clinical research, 03 medical and health sciences, 0302 clinical medicine, Piperidines, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Clinical endpoint, Humans, Anaplastic lymphoma kinase, Lung cancer, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Performance status, Crizotinib, business.industry, Middle Aged, medicine.disease, Confidence interval, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, business, medicine.drug
Abstract

Alectinib has shown marked efficacy and safety in patients with anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangement-positive NSCLC and a good performance status (PS). It has remained unclear whether alectinib might also be beneficial for such patients with a poor PS.Eligible patients with advanced ALK rearrangement-positive NSCLC and a PS of 2 to 4 received alectinib orally at 300 mg twice daily. The primary end point of the study was objective response rate (ORR), and the most informative secondary end point was rate of PS improvement.Between September 2014 and December 2015, 18 patients were enrolled in this phase II study. Of those patients, 12, five, and one had a PS of 2, 3, or 4, respectively, whereas four patients had received prior crizotinib treatment. The ORR was 72.2% (90% confidence interval: 52.9-85.8%). The ORR did not differ significantly between patients with a PS of 2 and those with a PS of 3 or higher (58.3% and 100%, respectively [p = 0.114]). The PS improvement rate was 83.3% (90% confidence interval: 64.8-93.1%, p0.0001), with the frequency of improvement to a PS of 0 or 1 being 72.2%. The median progression-free survival was 10.1 months. Toxicity was mild, with the frequency of adverse events of grade 3 or higher being low. Neither dose reduction nor withdrawal of alectinib because of toxicity was necessary.Alectinib is a treatment option for patients with ALK rearrangement-positive NSCLC and a poor PS.

Published
2017

3. P1.08-006 Phase I/II Study of Carboplatin, nab-paclitaxel, and Concurrent Radiation Therapy for Patients with Locally Advanced NSCLC

Author

Ryotaro Morinaga, Miyako Satouchi, Mitsuhiro Takenoyama, Junji Kishimoto, Takafumi Sasaki, Shinobu Hosokawa, Y. Nakanishi, Tomoki Kimura, M. Okuno, Y. Hisamatsu, Isamu Okamoto, Yuko Kawano, Atsushi Horiike, Hiroyuki Yamaguchi, Kazutoshi Komiya, K. Inoue, Yuka Fujita, and Katsuya Hirano

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Locally advanced, Carboplatin, Radiation therapy, chemistry.chemical_compound, Phase i ii, chemistry, Internal medicine, Medicine, business, Nab-paclitaxel
Published
2017

4. P1.03-004 Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status

Author

Takayuki Shimose, Akihiro Bessho, Yasushi Goto, Yuka Fujita, Y. Mori, Noriaki Nakagaki, A. Okazaki, Hirotsugu Kenmotsu, Noboru Yamamoto, Kenji Sugio, Masahiro Seike, Y. Nakanishi, Sunao Ushijima, Isamu Okamoto, Eiji Iwama, Shinsuke Tsumura, Hiroaki Akamatsu, Toshiyuki Harada, Akinobu Hamada, S. Tokunaga, Ryotaro Morinaga, Manabu Ono, and Hiroyuki Sakashita

Subjects
Pulmonary and Respiratory Medicine, Alectinib, Oncology, business.industry, Cancer research, medicine, Poor performance status, Non small cell, ALK Rearrangement, Lung cancer, medicine.disease, business
Published
2017

5. P2.03a-056 Phase II Trial of Weekly Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: KTOSG Trial 1301

Author

Hirotsugu Kohrogi, Aimi Enokizu, Yoichi Nakanishi, Yasuto Yoneshima, Ryotaro Morinaga, Kohei Otsubo, Susumu Hirosako, Hiroto Kishi, Shinji Fujii, Sho Saeki, Isamu Okamoto, Shinya Sakata, Eiji Iwama, Taishi Harada, Emi Yamaguchi, Yuichiro Koga, Naoko Aragane, and Kazutoshi Komiya

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, medicine.disease, Clinical trial, Internal medicine, medicine, Non small cell, Lung cancer, Previously treated, business, Nab-paclitaxel
Published
2017

6. P1-228: A combination phase I study of topotecan with carboplatin for relapsed small cell lung cancer: Results of West Japan Thoracic Oncology Group trial (WJTOG0202)

Author

Koji Takeda, Ryotaro Morinaga, Toshiro Miwa, Masashi Kobayashi, Nobuhiko Seki, Tatsuhiko Kashii, Masahiro Fukuoka, Masahiro Tsuboi, Taroh Satoh, and Takayasu Kurata

Subjects
Oncology, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Group trial, business.industry, Carboplatin, Phase i study, chemistry.chemical_compound, chemistry, Thoracic Oncology, Internal medicine, medicine, Topotecan, business, Relapsed Small Cell Lung Cancer, medicine.drug
Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results